...
首页> 外文期刊>Medicine. >Ginseng for managing menopausal woman's health: A systematic review of double-blind, randomized, placebo-controlled trials
【24h】

Ginseng for managing menopausal woman's health: A systematic review of double-blind, randomized, placebo-controlled trials

机译:人参管理绝经妇女健康:对双盲,随机,安慰剂对照试验的系统审查

获取原文
获取原文并翻译 | 示例

摘要

Background:The aim of this systematic review was to update, complete, and critically evaluate the evidence from placebo-controlled randomized clinical trials (RCTs) of ginseng for managing menopausal women's health.Methods:We searched the literature using 13 databases (MEDLINE, AMED, EMBASE, the Cochrane Library, 6 Korean Medical, and 3 Chinese Databases) from their inception to July 2016 and included all double-blind RCTs that compared any type of ginseng with a placebo control in postmenopausal women. The methodological quality of all studies was assessed using a Cochrane risk of bias tool.Results:Ten RCTs met our inclusion criteria. Most RCTs had unclear risk of bias. One RCT did not show a significant difference in hot flash frequency between Korean red ginseng (KRG) and placebo. The second RCT reported positive effects of KRG on menopausal symptoms. The third RCT found beneficial effects of ginseng (Ginsena) on depression, well-being, and general health. Four RCTs failed to show significant differences in various hormones between KRG and placebo controls except dehydroepiandrosterone. Two other RCTs failed to show effects of KRG on endometrial thickness in menopausal women. The other RCT also failed to show the effects of American ginseng on oxidative stress markers and other antioxidant enzymes.Conclusion:Our systematic review provided positive evidence of ginseng for sexual function and KRG for sexual arousal and total hot flashes score in menopausal women. However, the results of KRG or ginseng failed to show specific effects on hot flash frequency, hormones, biomarkers, or endometrial thickness. The level of evidence for these findings was low because of unclear risk of bias.
机译:背景:这种系统审查的目的是更新,完整,并批判性地评估人参的安慰剂对照随机临床试验(RCT)的证据,用于管理绝经妇女的健康。方法:我们使用13个数据库搜索了文献(Medline,Cameed从他们到2016年7月开始的成立并将所有双盲RCT与绝经后妇女的安慰剂对照中的所有类型的人参进行了双盲RCT,包括所有双盲RCT。使用偏置工具的Cochrane风险评估所有研究的方法论质量。结果:十个RCT符合我们的纳入标准。大多数RCT都不明确偏倚风险。一个RCT在韩国红手(KRG)和安慰剂之间没有显示出热闪频频率的显着差异。第二个RCT报告了KRG对更年期症状的积极影响。第三个RCT发现人参(GINSENA)对抑郁,福祉和一般健康的有益效果。除脱氢硫代酮外,四个rcts未能显示出KRG和安慰剂对照之间的各种激素的显着差异。另外两种RCT未能显示KRG对更长期妇女的子宫内膜厚度的影响。另一个RCT还未能展示美国人参对氧化应激标记物和其他抗氧化酶的影响。结论:我们的系统评价提供了人参的积极证据,为性函数和KRG进行了性唤醒,绝经热的闪光分数。然而,KRG或人参的结果未能对热闪光频率,激素,生物标志物或子宫内膜厚度表现出特定的影响。由于偏倚风险不明确,这些发现的证据水平很低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号